New trial tests early pill to slow silent kidney damage
NCT ID NCT06676007
Summary
This study is testing if starting a special, targeted-release steroid capsule called budesonide early can help control IgA nephropathy, a kidney disease. It will involve 200 adults recently diagnosed with the condition to see if the treatment safely reduces protein in their urine and slows kidney function decline over 12 months. The goal is to see if early treatment can better manage the disease and protect the kidneys.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Provincial People's Hospital
RECRUITINGChengdu, Sichuan, 610072, China
Conditions
Explore the condition pages connected to this study.